Drug Discovery World

APRIL 24, 2024

The strategic partnership will combine Variant Bio’s genomic discovery capabilities and VB-Inference platform with Evotec’s knowledge of antifibrotic drug discovery. Dr Matthias Evers, Chief Business Officer of Evotec, said: “We are excited to enter this collaboration with Variant Bio.

Development 52

Development In-Vivo In-Vitro Genome 52

Drug Discovery World

FEBRUARY 12, 2024

In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” It is becoming more broadly acknowledged that AI is set to transform one of the most promising yet under-utilised fields of omics – 3D genomics.

Genome 139

Genome Genomics Life Science Gene Therapy 139

BioPharma Reporter

FEBRUARY 8, 2024

Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs. Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry.

Genome 59

Genome Genomics Clinical Development Development 59

BioTech 365

AUGUST 11, 2020

Funding will be used to support ongoing clinical development of Scioto’s lead product, SB-121, as a microbiome treatment for diseases affecting the gut-brain axis and gut injury INDIANAPOLIS–(BUSINESS WIRE)–Scioto Biosciences announced today the closing of a strategic investment of up … Continue reading →

Genome 40

Genome Genomics Clinical Development Production 40

Worldwide Clinical Trials

FEBRUARY 6, 2023

When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed.

Genetics 130

Genetics Clinical Trials Clinical Trials Genotype 130

Drug Discovery World

JANUARY 11, 2024

Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need. In the first article, Allison August, M.D.,

Development 52

Development Drugs Genome Genomics 52

Outsourcing Pharma

APRIL 19, 2021

One Healthâs FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.

Research 113

Research Genome Genomics Development 113

Pharmaceutical Technology

FEBRUARY 13, 2023

The company expects that its platform and multimodal capabilities will lead to a new era of precision oncology by improving early diagnosis and patient identification, accelerating innovative medicines adoption along the care pathway and optimising clinical development.

Genetics 130

Genetics Development Drugs Genome 130

pharmaphorum

JULY 8, 2022

The aim is to overcome a very low success rate in drug discovery, with just 10% of candidates making it into clinical development despite the application of new computational technology techniques to handle an ever-growing amount of biomedical data, for example from genomics studies. billion, according to the report.

Drugs 131

Drugs Clinical Development Marketing Genome 131

Drug Discovery World

DECEMBER 15, 2022

The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. .

Clinical Trials 52

Clinical Trials Clinical Trials Genome Genomics 52

Drug Discovery Today

FEBRUARY 16, 2021

CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2. Celltrion has constructed a COVID-19 antibody portfolio and clinical development platform to help combat the spread of the virus mutations

Antibody 45

Antibody Development Genome Genomics 45

Drug Discovery World

MAY 31, 2023

They are called “ Predictive biomarkers in the age of spatial biology ”, “ Exploiting the microbiome to drive nature – inspired innovation ”, and “ Animal research: reinventing the norm ”.

Drugs 52

Drugs Genome Genomics Clinical Development 52

Drug Discovery World

MAY 31, 2023

They are called “ Predictive biomarkers in the age of spatial biology ”, “ Exploiting the microbiome to drive nature – inspired innovation ”, and “ Animal research: reinventing the norm ”.

Drugs 52

Drugs Genome Genomics Clinical Development 52

Drug Discovery World

JUNE 5, 2023

Meet the biotech: Enhanc3D Genomics Enhanc3D Genomics was spun out from the laboratories of Dr Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organisation of the genome at the Babraham Institute in Cambridge, UK.

Genome 52

Genome Genomics Life Science Genetics 52

Drug Discovery World

OCTOBER 14, 2022

Tavros’ functional and computational genomics technologies are designed to uncover unique vulnerabilities within tumours to discover novel targets and biomarkers in areas of high unmet clinical need. The future of cancer treatment lies in the precision targeting of therapies in the optimal clinical settings.

Genome 52

Genome Genomics Clinical Development Drugs 52

Scienmag

FEBRUARY 14, 2022

A study by researchers at Mayo Clinic Cancer Center in Florida is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from chemotherapy or from immunotherapy. JACKSONVILLE, FLA. ? The study is published in Nature Communications.

Clinical Research 84

Clinical Research Research Genome Genomics 84

Outsourcing Pharma

JANUARY 26, 2021

With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.

Genome 86

Genome Genomics Clinical Development Development 86

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

The Pharma Data

MARCH 1, 2022

A key element of this partnership involves Lifebit’s CloudOS platform – a powerful, secure and cutting-edge platform used by a growing number of research organizations and governments globally, such as Genomics England and The Hong Kong Genome Project.

Biobanking 52

Biobanking Genome Genomics Genome Project 52

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. These sequences are usually silenced in healthy cells but are activated and presented on tumour cells.

Genome 80

Genome Genomics Licensing Licensing 80

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development.

RNA 64

RNA In-Vivo In-Vitro DNA 64

pharmaphorum

SEPTEMBER 12, 2022

Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. Tailored oncology.

Genome 105

Genome Genomics Clinical Trials Clinical Trials 105

The Pharma Data

DECEMBER 13, 2020

which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. 14, 2020 10:00 UTC. BEIJING & CAMBRIDGE, Mass.–( He received his B.S.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Drug Discovery World

MARCH 30, 2023

According to data and analytics company Globaldata, the approval of LK101 injection sets the stage for exciting developments in the field. Neoantigens are produced by specific tumour viruses, integrated into the genome and are abundantly expressed only in tumour cells with strong immunogenicity and tumour heterogeneity.

Regulation 52

Regulation Vaccination Vaccine Trials 52

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.

Life Science 162

Life Science Development Gene Therapy Genetics 162

The Pharma Data

JANUARY 12, 2021

Dark Antigens are in reference to a newer class of cancer antigens derived from a portion of the human genome not normally expressed as a protein. This portion of the genome is dubbed the “genomic dark matter.” Additionally, Boehringer has been granted the responsibility for all non-clinical as well as clinical development.

Research 52

Research Genome Genomics Licensing 52

pharmaphorum

MARCH 2, 2021

Decentralised studies reduce or eliminate the need to travel to clinical sites, and the two partners want to go even further by harnessing technologies that can provide additional data in real-time to generate “a more holistic view of patient health,” according to Medable CEO Dr Michelle Longmire.

Trials 98

Trials Clinical Trials Clinical Trials Life Science 98

Drug Discovery World

MAY 25, 2023

They are designed to streamline pre-clinical development of antibody-based therapeutics, enabling immunogenicity screening of drug candidates without the need for drug-specific ADA assay development.

Production 52

Production Reagent DNA Drugs 52

pharmaphorum

JANUARY 24, 2022

Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.

Radiology 111

Radiology Marketing Genome Genomics 111

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. Drug discovery and development tomorrow – Changing the mindset. Clinical Development Success Rates 2006-2015.;

Medicine 59

Medicine Genome Genomics Drugs 59

pharmaphorum

OCTOBER 5, 2022

.” The partners are still in the discovery stage of the collaboration, and Sanofi will take full responsibility for the programme once a drug candidate to take forward into preclinical and clinical testing has been selected. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

OCTOBER 13, 2022

million in future payments tied to preclinical, clinical development, and commercial achievements. Bayer bought Vividion for $1.5 Vividion is making an upfront payment of $17.5 million to get the collaboration underway, with the objective of finding four targets that could generate another $430.5

Gene Therapy 64

Gene Therapy Genome Genomics Drugs 64

The Pharma Data

MARCH 23, 2021

The marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne ® CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fusion cancer who are expected to benefit from treatment with Vitrakvi. Fields, M.D., About Oncology at Bayer.

Genome 52

Genome Genomics Gene Protein 52

Drug Discovery World

FEBRUARY 27, 2024

While we have made a lot of progress in targeted therapeutics by identifying molecular tumour drivers that define patient subsets, genomics has not quite produced the same level of understanding for tumour-immune biology. Ron A : One of the most important problems to solve in drug discovery is improving the probability of clinical success.

Genome 52

Genome Genomics Genotype Medicine 52

Drug Discovery World

JUNE 19, 2023

This collaboration between PrecisionLife and Nanopharmaceutics uses mechanistic patient stratification biomarkers to inform clinical trial design and transform the lives of patients.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

KSQ and Takeda can collaborate on IND-enabling activities, with clinical development led by Takeda to explore multiple modalities. Takeda will assume responsibility for funding all development and commercialization activities. KSQ is also eligible to receive tiered royalties on net sales of each approved product.

Development 52

Development Research In-Vivo Genome 52

The Pharma Data

SEPTEMBER 25, 2020

The new funding will be used to accelerate the development of Monte Rosa’s pipeline, advance products into clinical testing and bolster its platform capability to design and develop precision medicines for genomically defined diseases with limited treatment options. “We Source link.

Protein 40

Protein Development Genome Genomics 40